TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Belite Bio, Inc. ADR ( (BLTE) ) just unveiled an announcement.
On December 1, 2025, Belite Bio announced the pricing of a $350 million underwritten public offering of American Depositary Shares, each representing one ordinary share, at $154.00 per ADS. The offering, expected to close on December 3, 2025, aims to support commercialization preparation, pipeline development, and general corporate purposes. This move is significant for Belite Bio as it seeks to strengthen its market position and advance its drug development efforts, particularly for its lead candidate, Tinlarebant.
The most recent analyst rating on (BLTE) stock is a Buy with a $194.00 price target. To see the full list of analyst forecasts on Belite Bio, Inc. ADR stock, see the BLTE Stock Forecast page.
Spark’s Take on BLTE Stock
According to Spark, TipRanks’ AI Analyst, BLTE is a Neutral.
Belite Bio faces significant financial challenges with no revenue and increasing losses, impacting its overall score. Technical indicators show neutral momentum, and valuation is unattractive with negative earnings. However, the earnings call highlights clinical advancements and financial stability, providing a positive outlook in the long term despite current financial difficulties.
To see Spark’s full report on BLTE stock, click here.
More about Belite Bio, Inc. ADR
Belite Bio is a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases with significant unmet medical needs, such as Stargardt disease type 1 and geographic atrophy in advanced dry age-related macular degeneration, as well as specific metabolic diseases. The company’s lead candidate, Tinlarebant, is an oral therapy aimed at reducing bisretinoid toxins in the eye and is undergoing various clinical trials.
Average Trading Volume: 102,002
Technical Sentiment Signal: Buy
Current Market Cap: $5.37B
See more insights into BLTE stock on TipRanks’ Stock Analysis page.